科研之友
微信
新浪微博
Facebook
分享链接
摘要
Owing to the limited therapeutic efficacy of glioma vaccines, new strategies are required to improve cancer vaccines. Our study aimed to assess the therapeutic efficacy of a glioma vaccine called STDENVANT. This vaccine, comprising glioma stem-like cell (GSC) lysate, dendritic cells (DCs), and Toll-like receptor (TLR) 9 agonist CpG motif-containing oligodeoxynucleotides (CpG ODNs), was assessed using a GL261-C57BL/6 orthotopic mouse model of glioma. STDENVANT markedly improved survival and tumor regression by enhancing anti-tumor immune function. Moreover, STDENVANT upregulated programmed death 1 (PD-1) and its ligand PD-L1 on effector T cells, DCs, and glioma tissues, resulting in the accumulation of regulatory T (Treg) cells in the brain and lymph nodes. Combinatorial administration of anti-PD-L1 antibody and STDENVANT conferred a greater survival advantage and decreased the Treg cell population in the brain. The present results indicate that PD-L1 blockade can promote tumor regression via STDENVANT in a mouse model of glioma, and combinatorial administration of anti-PD-L1 antibody and STDENVANT increases the therapeutic anti-tumor efficacy of treatment. @@@ What's new? Vaccines based on dendritic cells harbouring glioma stem-like cell (GSC)-associated antigens are a promising therapeutic avenue against glioma, but efficacy remains limited. Here, the authors assessed the efficacy of a novel glioma vaccine called STDENVANT containing GSC lysate, dendritic cells, and CpG adjuvant. STDENVANT improved survival and tumor regression by enhancing anti-tumor immune function in an orthotopic mouse model of glioma. Moreover, addition of anti-PD-L1 mAb enhanced the therapeutic potency of the vaccine and deterred Treg cell accumulation in the tumor microenvironment. The findings revealed the potential clinical efficacy of combinatorial administration of the GSC-based vaccine with PD-L1 blocking therapy.
- 出版日期2019-6-1
- 单位吉林大学
